ID IDXX Idexx Laboratories 로딩 중... : 애널리스트의 강세 및 약세 의견

작성자: 최근 저점에서 IDEXX 롱

Management raised full-year organic revenue and EPS guidance midpoint, citing continued strong recurring revenue momentum, innovation traction (InViewDX, CancerDx, Catalyst menu), and planned investments in international commercial expansion.

Terry Smith, Idexx Laboratories 비중 29% 축소; 펀드 공시.

Management notes that US owner economics are being squeezed by escalating veterinary clinic prices, which is driving a decline in routine care visits and accelerating a shift toward emergency/urgent care and value-focused, alternative care models. — A structural slowdown in routine veterinary visits in the US could dampen the volume of products sold through traditional clinics, pressuring companies with high US companion-animal exposure and shifting demand toward retail/online channels and urgent care centers.

Management's guidance for 2026 is positive, expecting 7-9% organic revenue growth and 10-14% EPS growth, driven by continued innovation adoption and commercial execution despite macro headwinds.